ACA
NBIX icon

Atlas Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Atlas Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4K Buy
376
+363
+2,792% +$53.9K 0.01% 675
2026
Q1 		$1.71K Hold
13
– – ﹤0.01% 892
2025
Q4 		$1.84K Buy
+13
New +$1.88K ﹤0.01% 853

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atlas Capital Advisors's NBIX Position: Q2 2026 in Review

Atlas Capital Advisors increased its Neurocrine Biosciences (NBIX) stake by 2,792% in Q2 2026, buying an estimated $53.9K and bringing the position to 376 shares worth $63.4K. The position accounts for 0.01% of the portfolio, ranked #675.

Atlas Capital Advisors first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Atlas Capital Advisors held 376 shares of Neurocrine Biosciences worth $63.4K as of Q2 2026.
  • Atlas Capital Advisors bought 363 Neurocrine Biosciences shares in Q2 2026, an estimated $53.9K.
  • Neurocrine Biosciences made up 0.01% of Atlas Capital Advisors's portfolio in Q2 2026, its #675 holding.
  • Atlas Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.